Randomization
Patients were randomized by 1:1 assignment to either the decitabine‐RDHAP group or the RDHAP group using computer‐generated randomization lists.Some patients, particularly those in the RDHAP group, discontinued the treatment or were lost to follow‐up due to economic distress, poor physical condition, poor tolerance to chemotherapy, the COVID‐19 pandemic, and rainstorm disaster in Henan in 2021, and finally, these patients were excluded from the study.